EUVIMEDEUVIMED entdecken
Crossref

SHIP1 agonist rosiptor inhibits platelet activation and thrombosis by modulating cAMP/cGMP and PI3K/PKC pathway

Li Zhang, Yujing Yuan, Yueyue Shen, Chaoying Hua, Meng Wu, Yi Xiao, Rui Zhang, Tao Liu, Fang Guo, Zhanzhan Yang, Gang Liu

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2025.178461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Li Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China; School of Pharmacy, Guizhou Medical Univers…. Hauptthemen laut MEDLINE: Platelet Activation, Thrombosis, Cyclic GMP, Cyclic AMP. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Department of Science and Technology of Hunan Province, Guizhou Provincial Health Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Normal platelet activation is critical for proper hemostasis, while abnormal activation can lead to thrombotic diseases. Therefore, searching for substances that can regulate platelet activation will be helpful in preventing and treating thrombotic diseases. Studies have pointed out that SHIP1 can regulate platelet activation, affecting clot retraction and integrin αIIbβ3 activation. Nevertheless, the role of the SHIP1 agonist rosiptor in regulating platelet functions has not been investigated. This study aimed to investigate the antiplatelet and antithrombotic effects of rosiptor. Human platelets were isolated and used to evaluate the regulatory effect of rosiptor on platelet functions. The results showed that rosiptor significantly inhibits platelet activation, including aggregation, secretion, integrin αIIbβ3 activation, and Ca2+ mobilization. Moreover, rosiptor inhibited FeCl3-induced mesenteric artery occlusive thrombus formation in mouse models in vivo. Notably, rosiptor did not significantly prolong tail bleeding time in mice. Mechanistically, the levels of cGMP and cAMP were measured using ELISA kits, and protein expression was detected by immunoblotting. Rosiptor enhanced cGMP and cAMP-dependent signal transduction and inhibited agonist-induced PI3K/PKC signaling pathway. In conclusion, our study suggests that rosiptor may have a potential therapeutic role in thrombotic diseases with a reduced risk of bleeding complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet ActivationThrombosisCyclic GMPCyclic AMPPhosphatidylinositol 3-KinasesPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPlatelet Aggregation InhibitorsAnimalsHumansMiceMaleProtein Kinase CSignal TransductionBlood PlateletsPlatelet AggregationMice, Inbred C57BLPlatelet Glycoprotein GPIIb-IIIa Complex

Stichwörter der Autor:innen

Platelet activationRosiptorSHIP1Thrombosis

Substanzen

Cyclic GMPCyclic AMPPhosphatidylinositol 3-KinasesPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesProtein Kinase CPlatelet Aggregation InhibitorsINPP5D protein, humanPlatelet Glycoprotein GPIIb-IIIa Complex

Autor:innen und Institutionen

  • Department of Pharmacology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China; School of Pharmacy, Guizhou Medical University, Guiyang, China.
  • Department of Pharmacology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
  • School of Pharmacy, Guizhou Medical University, Guiyang, China.
  • School of Pharmacy, Guizhou Medical University, Guiyang, China. Electronic address: yangzhanzhan@gmc.edu.cn.
  • Department of Pharmacology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China; Guizhou Provincial Key Laboratory of Pathogenesis and Drug Research on Common Chronic Diseases, Guizhou Medical U…

Förderung

  • Department of Science and Technology of Hunan Province
  • Guizhou Provincial Health Commission
  • National Natural Science Foundation of China
  • Guizhou Provincial Youth Science and Technology Talents Growth Project
  • Guizhou Provincial Natural Science Foundation

Zitieren

APA

Zhang, L., Yuan, Y., Shen, Y., Hua, C., Wu, M., Xiao, Y., Zhang, R., Liu, T., Guo, F., Yang, Z., & Liu, G. (2026). SHIP1 agonist rosiptor inhibits platelet activation and thrombosis by modulating cAMP/cGMP and PI3K/PKC pathway. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178461

Vancouver

Zhang L, Yuan Y, Shen Y, Hua C, Wu M, Xiao Y, et al. SHIP1 agonist rosiptor inhibits platelet activation and thrombosis by modulating cAMP/cGMP and PI3K/PKC pathway. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2025.178461

BibTeX
@article{Zhang2026,
  author = {Zhang, Li and Yuan, Yujing and Shen, Yueyue and Hua, Chaoying and Wu, Meng and Xiao, Yi and Zhang, Rui and Liu, Tao and Guo, Fang and Yang, Zhanzhan and Liu, Gang},
  title = {SHIP1 agonist rosiptor inhibits platelet activation and thrombosis by modulating cAMP/cGMP and PI3K/PKC pathway},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2025.178461}
}
Kostenlos starten →